Search results for "Telangiectasia"

showing 10 items of 32 documents

Health‐Related Quality of Life in Hereditary Hemorrhagic Telangiectasia

2007

Objective To assess and differentiate the health-related quality of life (HR-QoL) in patients with hereditary hemorrhagic telangiectasia (HHT). Study Design and Setting A prospective, open, cross-sectional questionnaire-based study (including the Short Form-36 Health Survey [SF-36]) performed by a tertiary care center. Results A total of 77 patients (36 females) were included. Except for one domain (bodily pain), the scores for all scales of the SF-36 were significantly reduced in comparison with normative data. The duration of epistaxis, the presence of hepatic involvement and gastrointestinal bleeding, and the number of visible telangiectases correlated with lower scores on several scales…

MaleGastrointestinal bleedingmedicine.medical_specialtyPediatricsCross-sectional studyHealth StatusMEDLINETelangiectases03 medical and health sciences0302 clinical medicineQuality of lifeRecurrenceSurveys and QuestionnairesmedicineHumansProspective Studies030223 otorhinolaryngologyProspective cohort studyTelangiectasiaHealth related quality of lifebusiness.industrymedicine.diseaseCross-Sectional StudiesOtorhinolaryngology030220 oncology & carcinogenesisQuality of LifePhysical therapyFemaleTelangiectasia Hereditary HemorrhagicSurgerymedicine.symptombusinessOtolaryngology–Head and Neck Surgery
researchProduct

Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.

2014

Abstract Introduction Epistaxis is the most frequent manifestation in hereditary hemorrhagic telangiectasia, in which no optimal treatment exists. It can lead to severe anemia and reduced quality of life. Positive effects of tranexamic acid, an antifibrinolytic drug, have been reported on epistaxis related to this disorder. We sought to evaluate the efficacy of treating nosebleeds in hereditary hemorrhagic telangiectasia with tranexamic acid. Materials and Methods In a randomized, double-blind, placebo controlled, cross-over phase IIIB study, 1 gram of tranexamic acid or placebo was given orally 3 times daily for 3 months for a total of 6 months. Results 22 patients were included in the int…

AdultMaleAntifibrinolyticTime Factorsmedicine.drug_classMedizinAdministration OralPlaceboDrug Administration ScheduleDouble blindQuality of lifeDouble-Blind MethodGermanymedicineHumansTelangiectasiaAgedDiminutionCross-Over Studiesbusiness.industryHematologyMiddle AgedAntifibrinolytic AgentsClinical trialEpistaxisTreatment OutcomeTranexamic AcidAnesthesiaFemaleTelangiectasia Hereditary Hemorrhagicmedicine.symptombusinessTranexamic acidmedicine.drugThrombosis research
researchProduct

High Fidelity Deep Sequencing Reveals No Effect of ATM, ATR, and DNA-PK Cellular DNA Damage Response Pathways on Adenovirus Mutation Rate

2019

This article belongs to the Section Animal Viruses.

0301 basic medicineMutation ratemutation rateDNA RepairDNA damageMutation rateviruseslcsh:QR1-502Eukaryotic DNA replicationAtaxia Telangiectasia Mutated ProteinsDNA-Activated Protein KinaseHuman Adenovirus Type 5BiologyDNA damage responsemedicine.disease_causelcsh:MicrobiologyArticleDeep sequencingCell Line03 medical and health scienceschemistry.chemical_compoundVirologymedicineHumansexperimental evolutionPolymeraseMutation030102 biochemistry & molecular biologyAdenoviruses HumanHigh-Throughput Nucleotide SequencingDNA virus3. Good healthCell biologyHuman adenovirus type 5body regions030104 developmental biologyInfectious DiseasesExperimental evolutionchemistrybiology.proteinHuman Adenovirus Type 5.DNADNA DamageSignal TransductionViruses
researchProduct

Study of the cytolethal distending toxin (CDT)-activated cell cycle checkpoint. Involvement of the CHK2 kinase.

2001

AbstractThe bacterial cytolethal distending toxin (CDT) triggers a G2/M cell cycle arrest in eukaryotic cells by inhibiting the CDC25C phosphatase-dependent CDK1 dephosphorylation and activation. We report that upon CDT treatment CDC25C is fully sequestered in the cytoplasmic compartment, an effect that is reminiscent of DNA damage-dependent checkpoint activation. We show that the checkpoint kinase CHK2, an upstream regulator of CDC25C, is phosphorylated and activated after CDT treatment. In contrast to what is observed with other DNA damaging agents, we demonstrate that the activation of CHK2 can only take place during S-phase. Use of wortmannin and caffeine suggests that this effect is no…

Intracellular FluidCell cycle checkpointCytolethal distending toxinCell Cycle ProteinsAtaxia Telangiectasia Mutated ProteinsBiochemistryS PhaseWortmanninchemistry.chemical_compoundStructural BiologyPhosphorylation0303 health sciences030302 biochemistry & molecular biologyCell CycleCell cycleProtein-Tyrosine Kinases3. Good healthCell biologyDNA-Binding Proteinsbiological phenomena cell phenomena and immunityWortmanninG2 PhaseCytolethal distending toxinBacterial ToxinsProto-Oncogene Proteins pp60(c-src)Biophysics[SDV.BC]Life Sciences [q-bio]/Cellular BiologyBiologyProtein Serine-Threonine KinasesCell Line03 medical and health sciencesCaffeineGeneticsHumanscdc25 PhosphatasesCHEK1Molecular Biology[SDV.BC] Life Sciences [q-bio]/Cellular Biology030304 developmental biologyCheckpoint 2 kinaseCyclin-dependent kinase 1Cell growthTumor Suppressor ProteinsCell BiologyG2-M DNA damage checkpointCDC25CAndrostadienesGenes cdcchemistryCancer researchHeLa CellsFEBS letters
researchProduct

Idiopathische makuläre Teleangiektasie (IMT) – Verlaufsbeobachtung mit und ohne Laserphotokoagulation

2010

Purpose The aim of this study was to evaluate the effectiveness of laser photocoagulation for idiopathic macular telangiectasia (IMT) by using the revised and simplified classification of Yannuzzi 2006. Patients and methods The Yannuzzi classification was used for a retrospective analysis of the medical records of all patients with idiopathic macular telangiectasia as diagnosed consecutively in the University Eye Clinic of Mainz in the time period from 1 / 02 to 12 / 06. Laser treatment was indicated only in those eyes which presented with a visual acuity below 10 / 20 (follow-up interval in median 37 months, minimum 13 months). Results 12 patients with unilateral macular telangiectasia (IM…

medicine.medical_specialtyVisual acuitygenetic structuresbusiness.industryLaser treatmentTreatment outcomeFollow up studiesMacular oedemamedicine.diseaseeye diseasesSurgeryOphthalmologyRetrospective analysisMedicinesense organsmedicine.symptombusinessMacular telangiectasiaKlinische Monatsblätter für Augenheilkunde
researchProduct

Primary biliary cirrhosis and hereditary hemorrhagic telangiectasia: When two rare diseases coexist

2013

Primary biliary cirrhosis is a slowly progressive cholestatic autoimmune liver disease that mainly affects middle- aged women with an estimated prevalence ranging from 6.7 to 402 cases per million. Hereditary hemorrhagic telangiectasia, or Rendu-Osler-Weber disease, is an autosomal dominant disorder characterized by angiodysplastic lesions (telangiectases and arteriovenous malformations) that can affect many organs, including liver, with a prevalence of 1-2 cases per 10000. We describe the coexistence, for the first time to our knowledge, of these two rare diseases in a 50-year old Caucasian woman. In this setting, the relevance of an accurate medical history, the role of liver histology an…

Pathologymedicine.medical_specialtySettore MED/12 - GastroenterologiaPrimary biliary cirrhosiHepatologybusiness.industryFocal nodular hyperplasiaCase ReportDiseaseTelangiectasesImmunostainingSettore MED/08 - Anatomia Patologicamedicine.diseaseUrsodeoxycholic acidPrimary biliary cirrhosisHereditary hemorragic telangiectasiaUrsodeoxycholic acidFocal nodular hyperplasiamedicineMedical historymedicine.symptomAutoimmune liver diseasebusinessTelangiectasiamedicine.drug
researchProduct

ATR expands embryonic stem cell fate potential in response to replication stress

2020

Fondazione Italiana per la Ricerca sul Cancro FIRC 18112 Sina Atashpaz.Fondazione Umberto Veronesi Sina Atashpaz Associazione Italiana per la Ricerca sul Cancro AIRC 5xmille METAMECH program Vincenzo Costanzo Giovanni Armenise-Harvard Foundation Vincenzo Costanzo European Research Council Consolidator grant 614541 Vincenzo Costanzo Associazione Italiana per la Ricerca sul Cancro Fellowship 23961 Negar ArghavanifarDanish Cancer Society KBVU-2014 Andres Joaquin Lopez-Contreras Danish Council for Independent Research Sapere Aude, DFF Starting Grant 2014 Andres Joaquin Lopez-Contreras European Research Council ERC-2015-STG-679068 Andres Joaquin Lopez-Contreras Danish National Research Foundatio…

0301 basic medicineEndogenyAtaxia Telangiectasia Mutated ProteinsMice0302 clinical medicineTandem Mass SpectrometryTranscription (biology)GENE ATRcell biologyCloning MolecularBiology (General)Cells Cultured0303 health sciencesGeneral NeuroscienceQRTotipotentCell DifferentiationEmbryoGeneral MedicineCell biologyMedicinebiological phenomena cell phenomena and immunityResearch ArticleQH301-705.5replication stressDNA damageScienceSettore MED/08 - Anatomia PatologicaBiologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesAnimalsRNA MessengerGeneEmbryonic Stem CellsmouseCell Proliferation030304 developmental biologyMessenger RNAGeneral Immunology and MicrobiologyChimeraSequence Analysis RNAEmbryogenesisTELOMERE ELONGATIONEPIGENETIC RESTRICTIONembryonic stem cellEmbryonic stem cellATR030104 developmental biologyGene Expression RegulationDNA-DAMAGECheckpoint Kinase 1GENOMIC STABILITY030217 neurology & neurosurgeryChromatography LiquidDNA DamageeLife
researchProduct

Glutathione levels in blood from ataxia telangiectasia patients suggest in vivo adaptive mechanisms to oxidative stress

2007

Objective: To evaluate an in vivo pro-oxidant state in patients with ataxia telangiectasia (AT). Methods: A set of oxidative stress endpoints were measured in 9 AT homozygotes, 16 AT heterozygotes (parents) and 83 controls (grouped in age ranges as for patients and parents, respectively). The following analytes were measured: (a) leukocyte 8-hydroxy-2-deoxyguanosine (8-OHdG); (b) blood glutathione (GSSG and GSH); and (c) plasma levels of glyoxal (Glx) and methylglyoxal (MGlx). Results: AT patients displayed a significant decrease in blood GSSG (p=0.012) and in MGlx plasma concentrations (P=0.012). A nonsignificant decrease in the GSSG:GSH ratio (p = 0.1) and a non-significant increase in 8-…

AdultMalemedicine.medical_specialtyAdolescentglyoxalClinical Biochemistryataxia telengiectasiamedicine.disease_causeAtaxia Telangiectasiachemistry.chemical_compoundIn vivoInternal medicinemethylglyoxalmedicineHumansataxia telangectasiaoxidative stressglutathioneChildoxidative streMethylglyoxalDeoxyguanosine8-Hydroxy-2'-deoxyguanosineHeterozygote advantageGeneral MedicineGlutathionePyruvaldehydemedicine.diseaseAdaptation Physiological8-Hydroxy-2'-deoxyguanosineEndocrinologychemistryBiochemistryChild PreschoolAtaxia-telangiectasiaFemaleataxia telangectasia; oxidative stress; glutathione; glyoxal; methylglyoxal; 8-Hydroxy-2'-deoxyguanosineOxidative stressTarget organDNA DamageClinical Biochemistry
researchProduct

germline mutations in women with familial breast cancer and a relative with haematological malignancy

2009

Biallelic inactivation of the ATM gene causes ataxia-telangiectasia (A-T), a complex neurological disease associated with a high risk of leukaemias and lymphomas. Mothers of A-T children, obligate ATM heterozygote mutation carriers, have a breast cancer (BC) relative risk of about 3. The frequency of ATM carriers in BC women with a BC family history has been estimated to be 2.70%. To further our clinical understanding of familial BC and examine whether haematological malignancies are predictive of ATM germline mutation, we estimated the frequency of heterozygote mutation carriers in a series of 122 BC women with a family history of both BC and haematological malignancy and without BRCA1/2 m…

OncologyCancer ResearchLymphomaDNA Mutational AnalysisCell Cycle ProteinsAtaxia Telangiectasia Mutated Proteins0302 clinical medicineBreast cancerGene FrequencyRisk FactorsMissense mutationGenetics0303 health scienceseducation.field_of_studyLeukemiafamilial breast cancerAtaxia–telangiectasiaPedigreeDNA-Binding ProteinsOncology030220 oncology & carcinogenesisMutation (genetic algorithm)EMMAFemaleAdultHeterozygotemedicine.medical_specialtyMolecular Sequence DataPopulationBreast NeoplasmsProtein Serine-Threonine KinasesBiologyRisk Assessment03 medical and health sciencesGermline mutationBreast cancerPredictive Value of TestsInternal medicinemedicineHumansGenetic Predisposition to DiseaseGenetic TestingeducationAllele frequencyGerm-Line Mutation030304 developmental biologyBase SequenceTumor Suppressor ProteinsHeterozygote advantagemedicine.diseaseAtaxia-telangiectasia
researchProduct

Different patterns of in vivo pro-oxidant states in a set of cancer- or aging-related genetic diseases

2008

A comparative evaluation is reported of pro-oxidant states in 82 patients with ataxia telangectasia (AT), Bloom syndrome (BS), Down syndrome (DS), Fanconi anemia (FA), Werner syndrome (WS), and xeroderma pigmentosum (XP) vs 98 control donors. These disorders display cancer proneness, and/or early aging, and/or other clinical features. The measured analytes were: (a) leukocyte and urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG), (b) blood glutathione (GSSG and GSH), (c) plasma glyoxal (Glx) and methylglyoxal (MGlx), and (d) some plasma antioxidants [uric acid (UA) and ascorbic acid (AA)]. Leukocyte 8-OHdG levels ranked as follows: WS>BS approximately FA approximately XP>DS approximately AT appr…

AdultMalemedicine.medical_specialtyDown syndromeXeroderma pigmentosumAdolescentmedicine.disease_causeBiochemistrychemistry.chemical_compoundAtaxia TelangiectasiaPhysiology (medical)Internal medicinemedicineHumansBloom syndromeChildAgedXeroderma PigmentosumMethylglyoxalDeoxyguanosineGlutathioneGlyoxalMiddle AgedAscorbic acidmedicine.diseasePyruvaldehydeGlutathioneEndocrinologyFanconi AnemiaantioxidantschemistryBiochemistry8-Hydroxy-2'-DeoxyguanosineUric acidOxidative streFemaleWerner SyndromeDown SyndromeReactive Oxygen SpeciesOxidative stressBloom SyndromeDNA Damage
researchProduct